This is the second part of an interview with David-Alexandre Gros, MD. For the first part, click here.
David-Alexandre C. Gros, MD
Credit: Eledon
EGenesis’s EGEN-2784 is a porcine kidney that features a number of genetic modifications intended to prevent rejection in human patients, and is under evaluation for the treatment of end-stage kidney disease alongside the use of Eledon Pharmaceuticals’ tegoprubart, an investigational monoclonal antibody intended to improve the efficacy and safety of kidney transplants. Following the announcement of that the transplant of an EGEN-2784 kidney had been completed in a second human patient CGTLive® reached out to David-Alexandre C. Gros, MD, Eledon’s chief executive officer, to get his insight on the news.
Gros spoke about how tegoprubart differs from traditional approaches to…